This guidance has been updated and replaced by NICE technology appraisal guidance 1118.
People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.